Clinical bottom line
Postoperative delirium (POD) is a common and serious complication in elderly general surgery patients, associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Current evidence supports multifactorial prevention strategies including risk stratification, non-pharmacologic interventions, and cautious use of pharmacologic agents. Emerging data suggest that perioperative use of intravenous acetaminophen may reduce delirium incidence in select surgical populations. However, definitive pharmacologic prevention and treatment options remain limited, and individualized care based on patient risk factors is essential.
What the evidence shows
Postoperative delirium affects a substantial proportion of elderly patients undergoing general surgery, with risk factors including advanced age, preexisting cognitive impairment, polypharmacy, and the type and duration of surgery (Gani et al., 2016). Risk prediction tools such as the Thoracic Delirium Index have been developed and validated in thoracic surgery cohorts, offering potential for broader application in elderly surgical patients to identify those at highest risk (2023 reviews).
Non-pharmacologic prevention remains the cornerstone of POD management. This includes orientation protocols, early mobilization, sleep hygiene, and minimization of sensory deprivation or overload (Popp et al., 2012). These interventions have demonstrated moderate efficacy in reducing delirium incidence and severity.
Pharmacologic approaches are less well established. The PANDORA trial investigated intravenous acetaminophen administered perioperatively in older cardiac surgery patients and reported a reduction in postoperative delirium incidence, suggesting a potential neuroprotective effect (Kernel Networks Inc. et al., 2019). However, extrapolation to general surgery requires caution due to differences in patient populations and surgical stress.
Other pharmacologic agents, including antipsychotics and sedatives, have shown inconsistent results and carry risks of adverse effects, limiting their routine use (Popp et al., 2012; Ullah et al., 2026). Current guidelines emphasize careful medication review and avoidance of deliriogenic drugs.
Early recognition and management of POD are critical. Multidisciplinary approaches involving surgeons, anesthesiologists, geriatricians, and nursing staff improve outcomes by facilitating timely intervention and supportive care.
Caveats and uncertainty
Most available data derive from heterogeneous surgical populations, often with a focus on cardiac or thoracic surgery, limiting direct applicability to general surgery. The evidence base for pharmacologic prevention in general surgery remains sparse and sometimes conflicting.
Risk prediction models require further validation across diverse surgical settings. The Thoracic Delirium Index, while promising, has yet to be widely tested outside thoracic surgery.
Pharmacologic interventions such as intravenous acetaminophen show promise but require larger, targeted trials in general surgery patients to confirm efficacy and safety. The optimal timing, dosing, and patient selection criteria remain undefined.
Non-pharmacologic strategies, though beneficial, depend heavily on institutional resources and staff training, which may limit implementation consistency.
How this may change practice
Surgeons managing elderly patients should incorporate routine delirium risk assessment into preoperative evaluation, potentially utilizing emerging predictive tools as they become validated for general surgery.
Implementing standardized, multidisciplinary delirium prevention protocols emphasizing non-pharmacologic measures can reduce POD incidence and improve recovery trajectories.
Consideration of perioperative intravenous acetaminophen as part of multimodal analgesia may offer additional delirium prevention benefits, pending further evidence in general surgery populations.
Enhanced awareness and early detection of POD should prompt prompt multidisciplinary intervention, minimizing complications and length of stay.
Future practice may evolve with validated risk stratification tools and targeted pharmacologic prophylaxis, but current management remains focused on comprehensive, individualized care.